Navigation Links
AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Date:5/9/2013

IRVINE, Calif., May 9, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner CardioNova has received written notification of approval of the Phase 1 protocol in its Investigational New Drug (IND) application with the Ministry of Healthcare of the Russian Federation (Minzdrav).  This notice clears CardioNova for distribution of the Phase 1 protocol to the participating clinical centers and application for its license to import AHRO-001 to conduct the Phase 1 trial.  CardioNova expects to obtain approval of its importation license in the next few weeks and commencement of patient screenings once drug product is in the control of the clinical research organization (CRO) conducting and monitoring the Phase 1 trial.

"We are thrilled to announce the achievement of another key milestone and we are now within weeks of commencement of human trials of AHRO-001," said AtheroNova CEO Thomas W. Gardner .  "Our partner CardioNova has been working tirelessly to ensure the fastest possible turnaround on any requests for supplemental information and we thank them for the extraordinary effort on this critical approval.  We have finished the packaging and labeling of AHRO-001 and eagerly await the notification of the approval for importation into the Russian Federation."

"We are delighted to have achieved this milestone approval for AHRO-001 and to be able to initiate clinical development of this exciting compound," commented Dr. Alexey Eliseev , Managing Director of Maxwell Biotech Group, CardioNova's parent company.

"We are excited that our many months of planning and effort will shortly result in the ini
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Psyche Systems Corporation and Luminate Health have ... platform that helps labs comply with new federal HHS ... way patients engage with these results, and improves provider ... a HIPAA-compliant digital platform that gives labs an easy ... lab results, and uniquely connects labs, physicians, and patients ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, ... in providing on-demand access to scientific, technical and medical ... with the Association of Southeastern Research Libraries (ASERL) ... research libraries located across 11 southeastern states. Founded in ... and collaborative programs to address the continually changing needs ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Franz ... technology, today announced that its flagship product, AllegroGraph, has ... Graph Database Market Update report. AllegroGraph is ... leveraging the W3C industry standards. Graph databases are skyrocketing in ... years, according to a recent DBMS ranking by ...
(Date:5/5/2015)... 5, 2015  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... 2015 on Friday, May 8 before the market opens. ... and conference call at 8:30 a.m. Eastern Time (5:30 ... be accessed by phone by calling (800) 708-4540 (domestic) ... can be accessed live on the Investors section of ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... Inc., a privately held molecular diagnostics company developing innovative ... announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. ... Metamark with over 20 years of experience in cancer ... Dr. Blume-Jensen was department head at EMD Serono, Inc. ...
... 16 Cord Blood America, Inc . ( ... the umbilical cord blood stem cell preservation company ... stem cells, a biological insurance policy, to families nationwide ... and CEO, was interviewed by analyst Francis Gaskins on ...
... LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... Healthcare Conference on Tuesday, September 21st at 12:30 PM ET ... audio broadcast over the Internet available at http://investor.sigmaaldrich.com/ . ... About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, 'Afford-A-Cord,' and Profitability 2
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Gladstone Institutes of Cardiovascular Disease (GICD) have found that ... the body is also an element in healthy skin ... 1 or DGAT1. Mice that lack DGAT1 have many ... diet-induced obesity, are more sensitive to insulin and leptin, ...
... release is available in German . , ... the 2009 Charles Rodolphe Brupbacher Prize for Cancer Research. Nubia ... tumours such as cervical cancer through human papilloma viruses and ... smoking. The prize from the Charles Rodolphe Brupbacher Foundation has ...
... This release is available in French and ... Granada , the Spanish National Research Council (CSIC) and the ... nacre,s growing mechanism of gastropods, a previous step for the ... possible its use in biomedicine, with applications such as the ...
Cached Biology News:Brupbacher prize to Nubia Munoz and Sir Richard Peto 2Brupbacher prize to Nubia Munoz and Sir Richard Peto 3A research work on molluscs nacre opens new doors for its possible use in biomedicine 2
Synaptotagmin, phosphoSer309...
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: